{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T18:45:23Z","timestamp":1775760323699,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T00:00:00Z","timestamp":1678147200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T00:00:00Z","timestamp":1678147200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>Visceral leishmaniasis (VL) is an endemic parasitic disease in Latin America, and its clinical picture is aggravated in coinfections with the human immunodeficiency virus (HIV). The objective of this study was to investigate clinical factors and laboratory variables associated with VL relapse and death in VL\/HIV coinfected patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A prospective longitudinal study was conducted from January 2013 to July 2020 among 169 patients coinfected with VL and HIV. The outcomes investigated were the occurrence of VL relapse and death. Chi-square test, Mann\u2013Whitney test and logistic regression models were used for statistical analysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The occurrence rates were 41.4% for VL relapse and 11.2% for death. Splenomegaly and adenomegaly were associated with the increased risk of VL relapse. Patients with VL relapse had higher levels of urea (<jats:italic>p<\/jats:italic>\u2009=\u2009.005) and creatinine (<jats:italic>p<\/jats:italic>\u2009&lt;\u2009.001). Patients who died had lower red blood cell counts (<jats:italic>p<\/jats:italic>\u2009=\u2009.012), hemoglobin (<jats:italic>p<\/jats:italic>\u2009=\u2009.017) and platelets (<jats:italic>p<\/jats:italic>\u2009&lt;\u2009.001). The adjusted model showed that antiretroviral therapy for more than 6\u00a0months was associated with a decrease in VL relapse, and adenomegaly was associated with an increase in VL relapse. In addition, edema, dehydration, poor general health status, and paleness were associated with an increase in hospital death.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The findings suggest that adenomegaly, antiretroviral therapy, and renal abnormalities can be associated with VL relapse, while hematological abnormalities, and clinical manifestations like paleness, and edema can be associated with an increased odds of hospital death.<\/jats:p>\n                <jats:p><jats:italic>Trial registration number:<\/jats:italic> The study was submitted to the Ethics and Research Committee of the Federal University of Maranh\u00e3o (Protocol: 409.351).<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-023-08009-1","type":"journal-article","created":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T00:17:12Z","timestamp":1680740232000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Factors associated with relapse and hospital death in patients coinfected with visceral leishmaniasis and HIV: a longitudinal study"],"prefix":"10.1186","volume":"23","author":[{"given":"Larissa D. L. N.","family":"Costa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uiara S.","family":"Lima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vandilson","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayara I. S.","family":"Lima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucilene A.","family":"Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorim","family":"Ithamar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Concei\u00e7\u00e3o M. P. S.","family":"Azevedo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,3,7]]},"reference":[{"key":"8009_CR1","doi-asserted-by":"publisher","DOI":"10.1590\/0037-8682-0240-2019","volume":"52","author":"TS Azevedo","year":"2019","unstructured":"Azevedo TS, Lorenz C, Chiaravalloti-Neto F. Risk mapping of visceral leishmaniasis in Brazil. Rev Soc Bras Med Trop. 2019;52: e20190240.","journal-title":"Rev Soc Bras Med Trop"},{"key":"8009_CR2","unstructured":"Pan American Health Organization. Leishmaniasis: Epidemiological Report in the Americas. Number 9, December 2020. Washington, D.C.: PAHO, 2020. Available at: https:\/\/iris.paho.org\/handle\/10665.2\/53090. Accessed 25 May 2021."},{"key":"8009_CR3","unstructured":"Minist\u00e9rio da Sa\u00fade, Departamento de Inform\u00e1tica do Sistema \u00danico de Sa\u00fade. Informa\u00e7\u00f5es de Sa\u00fade (TABNET): Epidemiol\u00f3gicas e Morbidade. Available at: http:\/\/www2.datasus.gov.br\/DATASUS\/index.php?area=0203. Accessed 25 May 2021."},{"key":"8009_CR4","doi-asserted-by":"publisher","first-page":"e0225875","DOI":"10.1371\/journal.pone.0225875","volume":"14","author":"URS Lima","year":"2019","unstructured":"Lima URS, Vanolli L, Moraes EC, Ithamar JS, Azevedo CMPES. Visceral leishmaniasis in Northeast Brazil: What is the impact of HIV on this protozoan infection? PLoS ONE. 2019;14:e0225875.","journal-title":"PLoS ONE"},{"key":"8009_CR5","unstructured":"Minist\u00e9rio da Sa\u00fade, Secretaria de Vigil\u00e2ncia em Sa\u00fade. Departamento de Vigil\u00e2ncia das Doen\u00e7as Transmiss\u00edveis. Manual de recomenda\u00e7\u00f5es para diagn\u00f3stico, tratamento e acompanhamento de pacientes com a coinfec\u00e7\u00e3o leishmania\u2013HIV. Bras\u00edlia, 2015. http:\/\/bvsms.saude.gov.br\/bvs\/publicacoes\/manual_recomendacoes_diagnostico_leishmania_hiv.pdf. Accessed 25 May 2021."},{"key":"8009_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0005772","volume":"11","author":"ML Sousa-Gomes","year":"2017","unstructured":"Sousa-Gomes ML, Romero GAS, Werneck GL. Visceral leishmaniasis and HIV\/AIDS in Brazil: are we aware enough? PLoS Negl Trop Dis. 2017;11: e0005772.","journal-title":"PLoS Negl Trop Dis"},{"key":"8009_CR7","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1590\/0037-8682-0494-2017","volume":"50","author":"GMC Viana","year":"2017","unstructured":"Viana GMC, Silva MACN, Garcia JVS, et al. Epidemiological profile of patients co\u2013infected with visceral leishmaniasis and HIV\/AIDS in Northeast. Brazil Rev Soc Bras Med Trop. 2017;50:613\u201320.","journal-title":"Brazil Rev Soc Bras Med Trop"},{"key":"8009_CR8","unstructured":"Minist\u00e9rio da Sa\u00fade, Secretaria de Vigil\u00e2ncia em Sa\u00fade. Departamento de Vigil\u00e2ncia, Preven\u00e7\u00e3o e Controle das Infec\u00e7\u00f5es Sexualmente Transmiss\u00edveis, do HIV\/Aids e das Hepatites Virais. Protocolo Cl\u00ednico e Diretrizes Terap\u00eauticas para Manejo da Infec\u00e7\u00e3o pelo HIV em Adultos, 2018. Available at: http:\/\/www.aids.gov.br\/pt-br\/pub\/2013\/protocolo-clinico-e-diretrizes-terapeuticas-paramanejo-da-infeccao-pelo-hiv-em-adultos. Accessed 25 May 2021."},{"key":"8009_CR9","unstructured":"Minist\u00e9rio da Sa\u00fade, Secretaria de Vigil\u00e2ncia em Sa\u00fade. Departamento de Vigil\u00e2ncia Epidemiol\u00f3gica. Leishmaniose visceral grave: normas e condutas. Bras\u00edlia: Minist\u00e9rio da Sa\u00fade, Secretaria de Vigil\u00e2ncia em Sa\u00fade; 2006."},{"issue":"6","key":"8009_CR10","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1590\/0037-8682-0258-2016","volume":"9","author":"DL Costa","year":"2016","unstructured":"Costa DL, Rocha RL, Chaves EB, Batista VG, Costa HL, Costa CH. Predicting death from kala-azar: construction, development, and validation of a score set and accompanying software. Rev Soc Bras Med Trop. 2016;9(6):728\u201340.","journal-title":"Rev Soc Bras Med Trop"},{"key":"8009_CR11","volume-title":"Exame cl\u00ednico","author":"CC Porto","year":"2008","unstructured":"Porto CC. Exame cl\u00ednico. 5a ed. Rio de Janeiro: Guanabara Koogan; 2008.","edition":"5a"},{"key":"8009_CR12","unstructured":"Minist\u00e9rio da Sa\u00fade, Secretaria de vigil\u00e2ncia em sa\u00fade. Departamento de vigil\u00e2ncia epidemiol\u00f3gica. Manual de vigil\u00e2ncia e controle da leishmaniose visceral. 1 ed. 5\u00ba reimpress\u00e3o. Bras\u00edlia, 2014. http:\/\/bvsms.saude.gov.br\/bvs\/publicacoes\/manual_vigilancia_controle_leishmaniose_visceral_1edicao.pdf. Accessed 25 May 2021."},{"key":"8009_CR13","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.bjid.2015.07.004","volume":"19","author":"LG T\u00e1vora","year":"2015","unstructured":"T\u00e1vora LG, Nogueira MB, Gomes ST. Visceral Leishmaniasis\/HIV co\u2013infection in northeast Brazil: evaluation of outcome. Braz J Infect Dis. 2015;19:651\u20136.","journal-title":"Braz J Infect Dis"},{"key":"8009_CR14","doi-asserted-by":"publisher","DOI":"10.1590\/0037-8682-0257-2018","volume":"52","author":"GO Santos","year":"2019","unstructured":"Santos GO, Jesus NPS, Cerqueira-Braz JV, Santos VS, Lemos LMD. Prevalence of HIV and associated factors among visceral leishmaniasis cases in an endemic area of Northeast Brazil. Rev Soc Bras Med Trop. 2019;52: e20180257.","journal-title":"Rev Soc Bras Med Trop"},{"key":"8009_CR15","first-page":"193","volume":"10","author":"JAL Lindoso","year":"2018","unstructured":"Lindoso JAL, Moreira CHV, Cunha MA, Queiroz IT. Visceral leishmaniasis and HIV coinfection: current perspectives. HIV AIDS. 2018;10:193\u2013201.","journal-title":"HIV AIDS"},{"key":"8009_CR16","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.4269\/ajtmh.17-0787","volume":"99","author":"DL Guedes","year":"2018","unstructured":"Guedes DL, Medeiros Z, Silva ED, et al. Visceral leishmaniasis in hospitalized HIV-infected patients in Pernambuco. Brazil Am J Trop Med Hyg. 2018;99:1541\u20136.","journal-title":"Brazil Am J Trop Med Hyg"},{"key":"8009_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0007995","volume":"14","author":"K Cloots","year":"2020","unstructured":"Cloots K, Burza S, Malaviya P, et al. Male predominance in reported Visceral Leishmaniasis cases: Nature or nurture? A comparison of population\u2013based with health facility\u2013reported data. PLoS Negl Trop Dis. 2020;14: e0007995.","journal-title":"PLoS Negl Trop Dis"},{"issue":"3","key":"8009_CR18","doi-asserted-by":"publisher","first-page":"e0009204","DOI":"10.1371\/journal.pntd.0009204","volume":"15","author":"P Dahal","year":"2021","unstructured":"Dahal P, Singh-Phulgenda S, Olliaro PL, Guerin PJ. Gender disparity in cases enrolled in clinical trials of visceral leishmaniasis: a systematic review and meta-analysis. PLoS Negl Trop Dis. 2021;15(3):e0009204. https:\/\/doi.org\/10.1371\/journal.pntd.0009204.","journal-title":"PLoS Negl Trop Dis."},{"key":"8009_CR19","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1007\/s004360000354","volume":"87","author":"H Zhang","year":"2001","unstructured":"Zhang H, Zhao J, Wang P, Qiao Z. Effect of testosterone on Leishmania donovani infection of macrophages. Parasitol Res. 2001;87:674\u20136.","journal-title":"Parasitol Res"},{"key":"8009_CR20","unstructured":"World Health Organization. Control of the leishmaniases: report of a meeting of the WHO Expert Commitee on the Control of Leishmaniases, Geneva, 2010. https:\/\/apps.who.int\/iris\/handle\/10665\/44412. Accessed 25 May 2021."},{"key":"8009_CR21","doi-asserted-by":"crossref","unstructured":"Yang YL, Xiang ZJ, Yang JH, Wang WJ, Xu ZC, Xiang RL. Adverse Effects Associated With Currently Commonly Used Antifungal Agents: A Network Meta-Analysis and Systematic Review. Front Pharmacol. 2021 https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC8585744\/. Accessed 28 May 2022.","DOI":"10.3389\/fphar.2021.697330"},{"key":"8009_CR22","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1097\/QAI.0000000000001843","volume":"79","author":"T Davy-Mendez","year":"2018","unstructured":"Davy-Mendez T, Napravnik S, Zakharova O, et al. Acute HIV infection and CD4\/CD8 ratio normalization after antiretroviral therapy initiation. J Acquir Immune Defic Syndr. 2018;79:510\u20138.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"8009_CR23","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1128\/CMR.10.2.298","volume":"10","author":"J Alvar","year":"1997","unstructured":"Alvar J, Ca\u00f1avate C, Guti\u00e9rrez-Solar B, et al. Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clin Microbiol Rev. 1997;10:298\u2013319.","journal-title":"Clin Microbiol Rev"},{"key":"8009_CR24","doi-asserted-by":"publisher","first-page":"e35","DOI":"10.1016\/S2468-2667(16)30020-2","volume":"2","author":"S Croxford","year":"2017","unstructured":"Croxford S, Kitching A, Desai S, et al. Mortality and causes of death in people diagnosed with HIV in the era of highly active antiretroviral therapy compared with the general population: an analysis of a national observational cohort. Lancet Publ Heal. 2017;2:e35-46.","journal-title":"Lancet Publ Heal"},{"key":"8009_CR25","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1111\/j.1365-3156.2010.02550.x","volume":"15","author":"Z Hurissa","year":"2010","unstructured":"Hurissa Z, Gebre-Silassie S, Hailu W, et al. Clinical characteristics and treatment outcome of patients with visceral leishmaniasis and HIV co\u2013infection in northwest Ethiopia. Trop Med Int Health. 2010;15:848\u201355.","journal-title":"Trop Med Int Health"},{"key":"8009_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.curtheres.2020.100583","volume":"92","author":"R Mohammed","year":"2020","unstructured":"Mohammed R, Fikre H, Schuster A, Mekonnen T, Griensven JV, Diro E. Multiple relapses of visceral leishmaniasis in HIV Co\u2013Infected Patientes: a case series from Ethiopia. Curr Ther Res. 2020;92: 100583.","journal-title":"Curr Ther Res"},{"key":"8009_CR27","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1017\/S003118201800080X","volume":"145","author":"I Fontoura","year":"2018","unstructured":"Fontoura I, Barbosa D, Andrade PAD, et al. Epidemiological, clinical and laboratory aspects of human visceral leishmaniasis (HVL) associated with human immunodeficiency virus (HIV) coinfection: a systematic review. Parasitol. 2018;145:1801\u201318.","journal-title":"Parasitol"},{"key":"8009_CR28","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1093\/cid\/civ530","volume":"61","author":"R Mahajan","year":"2015","unstructured":"Mahajan R, Das P, Isaakidis P, et al. Combination treatment for visceral leishmaniasis patients coinfected with human immunodeficiency virus in India. Clin Infect Dis. 2015;61:1255\u201362.","journal-title":"Clin Infect Dis"},{"key":"8009_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0001153","volume":"5","author":"GF Cota","year":"2011","unstructured":"Cota GF, De Sousa MR, Rabello A. Predictors of visceral leishmaniasis relapse in HIV-infected patients: a systematic review. PLoS Negl Trop Dis. 2011;5: e1153.","journal-title":"PLoS Negl Trop Dis"},{"key":"8009_CR30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0004087","volume":"9","author":"E Diro","year":"2015","unstructured":"Diro E, Ritmeijer K, Boelaert M, et al. Use of pentamidine as secondary prophylaxis to prevent visceral leishmaniasis relapse in HIV infected patients, the first twelve months of a prospective cohort study. PLoS Negl Trop Dises. 2015;9: e0004087.","journal-title":"PLoS Negl Trop Dises"},{"key":"8009_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4102\/sajhivmed.v19i1.817","volume":"19","author":"WDF Venter","year":"2018","unstructured":"Venter WDF, Fabian J, Feldman C. An overview of tenofovir and renal disease for the HIV-treating clinician. South Afr J HIV Med. 2018;19:1\u20138.","journal-title":"South Afr J HIV Med"},{"key":"8009_CR32","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.bjid.2018.03.001","volume":"22","author":"GAL Henn","year":"2018","unstructured":"Henn GAL, et al. Is Visceral Leishmaniasis the same in HIV\u2013coinfected adults? Braz J Infect Dis. 2018;22:92\u20138.","journal-title":"Braz J Infect Dis"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-08009-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-023-08009-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-08009-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T00:17:23Z","timestamp":1680740243000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-023-08009-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,7]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["8009"],"URL":"https:\/\/doi.org\/10.1186\/s12879-023-08009-1","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,7]]},"assertion":[{"value":"7 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was registered, receiving a favorable opinion from the Ethics and Research Committee of the Hospital Universit\u00e1rio do Maranh\u00e3o (Protocol: 409.351) of the city of S\u00e3o Lu\u00eds, state of Maranh\u00e3o, Brazil.\u00a0The patients in the study signed the Informed Consent Form, and their anonymity was guaranteed from the moment of data collection until the end of the research.\u00a0Authorization was also obtained from the Coordination of Staging and Research of the Maranh\u00e3o State Department of Health. All methods were performed in accordance with the relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"141"}}